Thermo Fisher Scientific Inc. $TMO Shares Bought by Hedeker Wealth LLC

Hedeker Wealth LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,845 shares of the medical research company’s stock after purchasing an additional 187 shares during the period. Hedeker Wealth LLC’s holdings in Thermo Fisher Scientific were worth $2,370,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Flossbach Von Storch SE lifted its holdings in Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after acquiring an additional 1,314,182 shares during the last quarter. Nuveen LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $532,360,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Thermo Fisher Scientific by 29.5% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after buying an additional 514,399 shares during the period. EdgePoint Investment Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $172,139,000. Finally, Lindsell Train Ltd boosted its holdings in Thermo Fisher Scientific by 68.0% during the second quarter. Lindsell Train Ltd now owns 854,612 shares of the medical research company’s stock valued at $346,511,000 after purchasing an additional 345,822 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on TMO shares. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a research note on Tuesday, October 28th. Robert W. Baird raised their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Barclays boosted their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $601.65.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the sale, the executive vice president owned 21,152 shares in the company, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the transaction, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. This represents a 41.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 52,341 shares of company stock worth $29,204,998. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.2%

Thermo Fisher Scientific stock opened at $579.12 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The firm’s fifty day moving average price is $527.90 and its 200-day moving average price is $468.04. The stock has a market cap of $217.58 billion, a P/E ratio of 33.46, a PEG ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter last year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.